Zembrace Symtouch is a drug owned by Tonix Medicines Inc. It is protected by 3 US drug patents filed from 2020 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 29, 2036. Details of Zembrace Symtouch's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11364224 | Pharmaceutical composition for treating migraine |
Jan, 2036
(11 years from now) | Active |
| US12097183 | Pharmaceutical composition for treating migraine |
Jan, 2036
(11 years from now) | Active |
| US10537554 | Pharmaceutical composition for treating migraine |
Jan, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zembrace Symtouch's patents.
Latest Legal Activities on Zembrace Symtouch's Patents
Given below is the list of recent legal activities going on the following patents of Zembrace Symtouch.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US10537554 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US11364224 |
| Email Notification Critical | 24 Apr, 2024 | US10537554 |
| Email Notification Critical | 24 Apr, 2024 | US11364224 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 15 Apr, 2024 | US10537554 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 15 Apr, 2024 | US11364224 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Jul, 2023 | US10537554 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Jun, 2022 | US11364224 |
| Recordation of Patent Grant Mailed Critical | 21 Jun, 2022 | US11364224 |
| Email Notification Critical | 02 Jun, 2022 | US11364224 |
US patents provide insights into the exclusivity only within the United States, but Zembrace Symtouch is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zembrace Symtouch's family patents as well as insights into ongoing legal events on those patents.
Zembrace Symtouch's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zembrace Symtouch's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 29, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zembrace Symtouch Generic API suppliers:
Sumatriptan Succinate is the generic name for the brand Zembrace Symtouch. 30 different companies have already filed for the generic of Zembrace Symtouch, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zembrace Symtouch's generic
Alternative Brands for Zembrace Symtouch
Zembrace Symtouch which is used for treating migraine headaches., has several other brand drugs using the same active ingredient (Sumatriptan Succinate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Currax |
| ||
| Endo Operations |
| ||
| Meridian Medcl |
| ||
| Teva Branded Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan Succinate, Zembrace Symtouch's active ingredient. Check the complete list of approved generic manufacturers for Zembrace Symtouch
About Zembrace Symtouch
Zembrace Symtouch is a drug owned by Tonix Medicines Inc. It is used for treating migraine headaches. Zembrace Symtouch uses Sumatriptan Succinate as an active ingredient. Zembrace Symtouch was launched by Tonix Meds in 2016.
Approval Date:
Zembrace Symtouch was approved by FDA for market use on 28 January, 2016.
Active Ingredient:
Zembrace Symtouch uses Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Sumatriptan Succinate ingredient
Treatment:
Zembrace Symtouch is used for treating migraine headaches.
Dosage:
Zembrace Symtouch is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | SOLUTION | Prescription | SUBCUTANEOUS |